5-Chloro-2,4-dihydroxypyridine
| Title | Journal |
|---|---|
| Pharmacokinetic study of weekly (days 1-5) low-dose S-1 in patients with non-small-cell lung cancer. | Reviews on recent clinical trials 20120501 |
| Comparison of three derivatization reagents for the simultaneous determination of highly hydrophilic pyrimidine antitumor agents in human plasma by LC-MS/MS. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120415 |
| Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer. | Cancer chemotherapy and pharmacology 20120401 |
| Substrate/Product-targeted NMR monitoring of pyrimidine catabolism and its inhibition by a clinical drug. | ACS chemical biology 20120316 |
| The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization. | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20120301 |
| Cystoid macular edema associated with oral antineoplastic agent s-1 in a patient with diabetic retinopathy. | Case reports in ophthalmology 20120101 |
| Pharmacokinetic study of S-1 in patients in whom inulin clearance was measured. | Oncology 20120101 |
| Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment. | Cancer research and treatment : official journal of Korean Cancer Association 20111201 |
| The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP). | The oncologist 20111001 |
| Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. | Cancer science 20110901 |
| Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer. | American journal of clinical oncology 20110801 |
| The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. | Cancer chemotherapy and pharmacology 20110801 |
| A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. | Cancer chemotherapy and pharmacology 20110601 |
| Proteomic differential display analysis for TS-1-resistant and -sensitive pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. | Anticancer research 20110601 |
| [Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110501 |
| Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer. | Cancer chemotherapy and pharmacology 20110401 |
| CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. | British journal of cancer 20110329 |
| Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. | British journal of cancer 20110215 |
| A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil. | Anticancer research 20110201 |
| Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. | PloS one 20110101 |
| A case of diffuse alveolar hemorrhage associated with tegafur plus uracil and warfarin therapy. | Clinical medicine insights. Case reports 20110101 |
| Pancreatic cancer: chemotherapy and radiotherapy. | North American journal of medical sciences 20110101 |
| An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. | Cancer chemotherapy and pharmacology 20101101 |
| Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. | Oncology reports 20101101 |
| Chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine predicts outcome of gastric cancer patients receiving S-1 postoperatively. | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20101101 |
| Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry. | Journal of pharmaceutical and biomedical analysis 20100801 |
| Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20100801 |
| Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1? | Cancer chemotherapy and pharmacology 20100701 |
| N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU. | Cancer chemotherapy and pharmacology 20100501 |
| [Construction of a system for proper TS-1 application]. | Gan to kagaku ryoho. Cancer & chemotherapy 20100301 |
| Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. | International journal of cancer 20100215 |
| Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer. | Japanese journal of clinical oncology 20100101 |
| A Phase II Study of S-1 Monotherapy as a First-line Combination Therapy of S-1 Plus Cisplatin as a Second-line Therapy, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma: A Second Report. | Clinical Medicine Insights. Oncology 20100101 |
| Concurrent chemoradiotherapy with S-1 for T2N0 glottic squamous cell carcinoma. | Journal of radiation research 20100101 |
| Gemcitabine and s-1 combination chemotherapy in patients with advanced biliary tract cancer: a retrospective study. | Case reports in oncology 20100101 |
| Stereotactic body radiation therapy boost in locally advanced pancreatic cancer. | International journal of radiation oncology, biology, physics 20091201 |
| Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. | Cancer chemotherapy and pharmacology 20091001 |
| S-1 mediates the inhibition of lymph node metastasis in oral cancer cells. | Oncology reports 20091001 |
| Simultaneous determination of tegafur and gimeracil in human plasma by liquid chromatography/tandem mass spectrometry. | Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20091001 |
| Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. | British journal of cancer 20090721 |
| High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. | British journal of cancer 20090707 |
| Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine). | Drug metabolism and disposition: the biological fate of chemicals 20090701 |
| Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas. | Annals of oncology : official journal of the European Society for Medical Oncology 20090501 |
| Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer. | Anticancer research 20090501 |
| Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. | Japanese journal of clinical oncology 20090101 |
| Pharmacokinetic study of S-1. | International journal of clinical pharmacology and therapeutics 20090101 |
| High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. | Cancer chemotherapy and pharmacology 20081201 |
| Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene. | International journal of clinical oncology 20081201 |
| [Case report of gastric cancer patient who suffered life-threatening adverse events including severe myelosuppression during neoadjuvant chemotherapy with S-1 and CDDP combination]. | Gan to kagaku ryoho. Cancer & chemotherapy 20080901 |
| A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. | British journal of cancer 20080819 |
| Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. | Cancer letters 20080818 |
| The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium. | Cancer chemotherapy and pharmacology 20080801 |
| [Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study]. | Zhonghua yi xue za zhi 20080527 |
| CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. | Cancer science 20080501 |
| Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. | British journal of cancer 20080325 |
| [Marked effect of combination chemotherapy with tegafur-gimeracil-oteracil potassium and gemcitabine on a suspected case of pancreas cancer or gallbladder cancer metastasis to bone: further diagnosis of disseminated carcinomatosa of bone marrow recurrence after the 23 years of gastric cancer operation by autopsy findings]. | Gan to kagaku ryoho. Cancer & chemotherapy 20080301 |
| S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer. | The Korean journal of internal medicine 20080301 |
| [A case of drug-induced interstitial pneumonia caused by TS-1]. | Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20080301 |
| A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20080101 |
| Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. | Anticancer research 20080101 |
| Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients. | Cancer chemotherapy and pharmacology 20071001 |
| Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism. | Journal of gastroenterology 20071001 |
| Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells. | Molecular cancer therapeutics 20070801 |
| A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. | British journal of cancer 20070604 |
| Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium. | Drug metabolism and pharmacokinetics 20070601 |
| Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. | British journal of cancer 20070507 |
| [Successful low-dose TS-1 administration in an elderly colon cancer patient with liver metastasis]. | Gan to kagaku ryoho. Cancer & chemotherapy 20070401 |
| The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer. | BJU international 20070301 |
| Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil. | Cancer chemotherapy and pharmacology 20060801 |
| Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer. | Oncology reports 20060801 |
| Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. | British journal of cancer 20060605 |
| [Pharmacokinetics of S-1]. | Gan to kagaku ryoho. Cancer & chemotherapy 20060601 |
| [Combination chemotherapy with S-1 and cisplatin for non-small cell lung cancer]. | Gan to kagaku ryoho. Cancer & chemotherapy 20060601 |
| Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. | British journal of cancer 20060424 |
| Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1. | Anti-cancer drugs 20060401 |
| DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer. | Anticancer research 20060101 |
| Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs. | Anticancer research 20060101 |
| Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model. | Anti-cancer drugs 20051101 |
| Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. | British journal of cancer 20051017 |
| [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function]. | Gan to kagaku ryoho. Cancer & chemotherapy 20051001 |
| The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. | Lung cancer (Amsterdam, Netherlands) 20050901 |
| Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts. | Oncology reports 20050701 |
| Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase. | Lung cancer (Amsterdam, Netherlands) 20050701 |
| Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. | British journal of cancer 20050620 |
| [TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)]. | Gan to kagaku ryoho. Cancer & chemotherapy 20050601 |
| Phase II study of S-1 in patients with advanced biliary tract cancer. | British journal of cancer 20041115 |
| Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. | British journal of cancer 20041004 |
| Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. | British journal of cancer 20040816 |
| Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation. | Drug metabolism and disposition: the biological fate of chemicals 20040701 |
| The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040615 |
| The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. | Anti-cancer drugs 20040201 |
| Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis. | Oncology 20040101 |
| Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. | British journal of cancer 20031215 |
| Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. | Anti-cancer drugs 20031001 |
| Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. | British journal of cancer 20030901 |
| Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma. | British journal of cancer 20030818 |
| Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. | Cancer chemotherapy and pharmacology 20030701 |
| Effect of combination of TS-1 and low-dose cisplatin on sarcoma-180 mouse sarcoma. | Anti-cancer drugs 20030701 |
| Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). | European journal of cancer (Oxford, England : 1990) 20030601 |
| Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. | International journal of clinical oncology 20030601 |
| EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. | British journal of cancer 20030310 |
| Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma. | European journal of cancer (Oxford, England : 1990) 20030301 |
| S-1 in gastric cancer: a comprehensive review. | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20030101 |
| Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. | Cancer chemotherapy and pharmacology 20020701 |
| A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur. | Pharmacogenetics 20020601 |
| Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. | European journal of cancer (Oxford, England : 1990) 20020601 |
| Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. | British journal of cancer 20020121 |
| Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. | The oncologist 20020101 |
| Increased intestinal permeability correlates with gastrointestinal toxicity among formulations of the fluorouracil analogue tegafur in rats. | European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes 20020101 |
| Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats. | The Journal of pharmacology and experimental therapeutics 20010601 |
| [New oral anticancer drug, TS-1 (S-1)--from bench to clinic]. | Gan to kagaku ryoho. Cancer & chemotherapy 20010601 |
| The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. | European journal of cancer (Oxford, England : 1990) 20010301 |
| Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010301 |
| Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: report of a case. | Oncology 20010101 |
| Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil. | Anticancer research 20010101 |